TNFSF14 and plasma cell myeloma: While for patients with NSCLC (Brunetti et al., 2020), multiple myeloma (Brunetti et al., 2014; Brunetti et al., 2018), and breast cancer (Gantsev et al., 2013), an increased pattern of LIGHT expression predicted a much worse survival.